Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.
Status:
Not yet recruiting
Trial end date:
2025-03-02
Target enrollment:
Participant gender:
Summary
Nowadays, no single drug is approved to treat rheumatoid arthritis-related interstitial lung
disease (RA-ILD). The medical management of this clinical condition is empirical and
controversial. There is preliminary data that tofacitinib may have a beneficial effect in
treating RA-ILD. Tofacitinib may have a double role in treating RA-ILD: treat RA disease
activity and an anti-fibrotic possible impact. Moreover, tofacitinib may be used as
monotherapy for the treatment of rheumatoid arthritis (RA) This is a phase IIa clinical trial
to evaluate the safety and tolerability of tofacitinib in RA-ILD patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Respiratory Diseases, Mexico